

B1 Sub-C

11. (New) The method of claim 10, wherein said nucleic acid sequence is inserted into a region essential for the replication of said viral vector.

12. (New) The method of claim 10, wherein said nucleic sequence encodes a polypeptide having thrombolytic properties.

13. (New) The method of claim 10, wherein said nucleic acid sequence encloses a polypeptide which is all or part of a dystrophin gene product.

14. (New) The method of claim 10 wherein said promoter is a promoter contained in the long terminal Repeat of a Rous Sarcoma Virus.

15. (New) A composition for treatment of muscular diseases comprising (i) a non replicative recombinant viral vector wherein said viral vector comprises a polynucleotide sequence under the control of a promoter recognized by polymerases of muscle cells and wherein said polypeptide is expressed in said muscle cells, associated with (ii) a pharmaceutically acceptable carrier.

16. (New) The composition of claim 15 wherein said muscular disease is a cardiac disease.

REMARKS

By way of the present preliminary amendment, Applicant has cancelled claim 1 and added claims 10–16. No new matter is added by this amendment. Claims 10–16 are pending in the instant application. Applicants respectfully submit that the claims are supported by the specification.

If the Examiner believes a telephone conference would advance the prosecution of this application, the Examiner is invited to telephone the undersigned at the below-listed telephone number.

Respectfully submitted,

Merchant & Gould P.C.
3100 Norwest Center
90 South Seventh Street
Minneapolis, MN 55402
612/332-5300

Dated: Dec 6, 1999

Mark T. Skoog
Mark T. Skoog
Reg. No. 40,178
MTS:PSTslc